Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: This application discloses an energy storage system including an energy storage apparatus and a cooling apparatus, where the energy storage apparatus includes an energy storage module and a power module, the cooling apparatus includes a first heat exchange mechanism, and the energy storage module and the power module are in thermally-conductive connection with the first heat exchange mechanism.

Abstract: The present disclosure provides compounds that are cGAS antagonists, solid forms of the compounds, methods of preparation of the compounds and their solid forms, pharmaceutical compositions comprising the compounds and their solid forms, and their use in medical therapy.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: A gas protection system, a gas protection method, and an energy storage system are provided. The gas protection system includes: a gas transmission pipe in communication with a sealed cabinet, where the gas transmission pipe is configured to input and output a protective gas to and from the sealed cabinet; a first detection module disposed in the gas transmission pipe; and a gas supply module configured to acquire gas parameters of the protective gas in the gas transmission pipe from the first detection module and supply a gas to the sealed cabinet based on the gas parameters.

Abstract: An energy storage system includes: an inlet main pipe and an outlet main pipe; a first branch pipe, connected between the inlet main pipe and the outlet main pipe, and including a first inlet branch pipe and a first outlet branch pipe; a second branch pipe, connected between the inlet main pipe and the outlet main pipe, and including a second inlet branch pipe and a second outlet branch pipe; a battery module unit, connected in series between the first inlet branch pipe and the first outlet branch pipe; and a power module unit, connected in series between the second inlet branch pipe and the second outlet branch pipe.

Abstract: A firefighting system and an energy storage system. The firefighting system includes: a sealed compartment, a circulation system, and a supply system. The sealed compartment is configured to accommodate at least one energy storage unit; the circulation system includes a circulation pipeline and a gas driving assembly, where two ends of the circulation pipeline are in communication with the sealed compartment to form a gas circulation loop; the gas driving assembly is disposed in the gas circulation loop; and a flame-retardant gas supply system is connected to the circulation system.

Abstract: The present application in one embodiment provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X1, X2, X3, X4, X5, X6, Y1, Y2, Y3, R7, R8, R9, R10, RA, RB, W and Cy1 are as described herein. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, autoimmune diseases, and inflammatory diseases are also provided.

Abstract: A method and system for active control of road network traffic congestion, and in particular, to the technical field of traffic congestion control includes: constructing a directed graph according to the positions of detectors in a road network; determining a free-flow reachability matrix of the directed graph and a plurality of neighborhood matrices with different orders according to a free-flow vehicle speed between cross-sections where the detectors are located and the directed graph; calculating a convolution operator of the directed graph within a set time period; inputting the convolution operator of the directed graph within the set time period into a long short-term memory neural network model to obtain a traffic state of each cross-section at each moment within a predicted time period; and determining whether a control method for each cross-section is single-point control or circle layer control.

Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.

Abstract: A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure provides a method and system for quantifying a degree of blending of virgin and aged asphalt in HRAM. The method includes the following steps: first, constructing a relational equation between the microscale modulus of recycled asphalt in a fully blended state and the content of the aged asphalt; measuring the microscale modulus of the recycled asphalt, the microscale modulus of the aged asphalt, the microscale modulus of the virgin asphalt, and the content of the aged asphalt in the HRAM in situ; inputting the dates above into the relational equation to obtain the microscale modulus of the recycled asphalt in the fully blended state; and based on the microscale modulus of the recycled asphalt measured in situ and the microscale modulus of the recycled asphalt in the fully blended state, obtaining the degree of blending of the virgin and aged asphalt in the HRAM.

Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.

Abstract: Disclosed are an accelerated test data analysis method and apparatus based on a grey forecast model, a device.

Abstract: The present disclosure discloses a method and apparatus for estimating product lifetime based on a multi-stress accelerated test, and a device. This method can be applied in the field of data processing technologies, specifically including: determining, in response to a lifetime estimation request for a target product, a target characteristic lifetime of the target product based on a target stress condition for the target product and correspondence relationships between candidate stress conditions and candidate characteristic lifetimes; and determining, based on an optimal lifetime model for the type to which the target product belongs and the target characteristic lifetime, a target average life of the target product.

Abstract: A performance degradation-based product reliability weak link evaluation method includes: acquiring a performance degradation parameter of each component of a to-be-evaluated product corresponding to each test time point; evaluating the performance degradation parameter of each component corresponding to each test time point through a fault time evaluation model, to obtain a pre-fault operating duration of each component; evaluating the pre-fault operating duration of each component through a confidence-based unreliability evaluation method, to obtain an unreliability evaluation result of each component; generating at least one component service life distribution model corresponding to each component according to the unreliability evaluation result, and selecting a corresponding target component service life distribution model; and evaluating mean time between failures corresponding to each component according to the target component service life distribution model, and selecting a reliability weak link of th

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.